Polycomb group proteins (PcG) are important epigenetic regulators that function to maintain transcriptional repression. These proteins assemble into two major complexes in mammals, designated Polycomb Repressive Complex 1 (PRC1) and 2 (PRC2). The core components of the PRC2 complex include EZH1/2, SUZ12, EED, and RBAP46/48. Several other cofactors, such as JARID2, AEBP2 and Polycomb-like proteins (PCL1/PHF1, PCL2/ MTF2, PCL3/PHF19) act as recruiters or modulators of PRC2 enzymatic activity [1] [2] [3] [4] . PRC2 catalyzes the trimethylation of histone H3 lysine 27 (H3K27me3), a marker of transcriptional repression, via its methyltransferase subunits EZH1/2 5 . However, the components of PRC1 are considerably heterogeneous. For example, each of the Drosophila subunits has several homologs in mammals that assemble to form different PRC1 complex types. The core components of the canonical PRC1 complex include RING1A/B, PCGF, CBX, and PHC 6 . PRC1 monoubiquitinates histone H2A at lysine 119 (H2AK119ub) through the E3 ligase activity of RING1A/B, thereby contributing to gene silencing 7 . PRC2 and PRC1 are proposed to interact with each other to maintain gene repression. Canonically, PRC2 'writes' H3K27me3 on chromatin of a given target gene locus, followed by binding of PRC1 to H3K27me3, leading to monoubiquitylation of H2A and subsequent chromatin compaction, and ultimately, gene repression 8 . Recent studies have shown that PRC1 can be recruited to target loci in a H3K27me3-independent manner and PRC1-dependent H2AK119ub1 recruits PRC2 to target genes 6, 9 . PcG proteins are involved in multiple biological processes, including maintenance of cell identity, differentiation, proliferation, and cancer progression [10] [11] [12] [13] [14] [15] . Drosophila Polycomb protein (Pc) binds to H3K27me3 through a conserved N-terminal chromodomain 16 . Five orthologues of Drosophila Pc exist in mammals (CBX2, CBX4, CBX6, CBX7 and CBX8). Accumulating evidence supports critical roles of CBX proteins in tumorigenesis [17] [18] [19] . Remarkably, CBX proteins can act as either oncogenes or tumor suppressors in different cancer types. For example, CBX7 functions as a tumor suppressor and its expression is negatively associated with increased malignancy grades in bladder, pancreatic, glioma, breast, gastric, and colon carcinomas 20 . Conversely, CBX7 is overexpressed in prostate and ovarian cancer, implying an oncogenic role in these cancer types 20 . CBX8 acts as an oncogene in hepatocellular carcinoma (HCC) and promotes tumor growth and metastasis via activation of AKT/β-catenin signaling 21 , but suppresses cell migration, invasion and metastasis in esophageal squamous cell carcinoma (ESCC) and inhibits epithelial-mesenchymal transition (EMT) by repressing SNAIL expression 22 . The results of our primary study suggest that CBX6 is downregulated in glioblastomas and its overexpression reduces cell proliferative capacity 23 . However, frequent upregulation of CBX6 in HCC in association with promotion of cancer cell growth, both in vitro and in vivo, and poor prognosis has also been reported 24 . Therefore, the functions of individual CBX proteins in any cancer type should be investigated separately. While a number of CBX proteins, such as CBX2, 4, 7, and 8, have been shown to play vital roles in breast cancer progression [25] [26] [27] [28] , the specific function of CBX6 in breast cancer progression remains to be elucidated.
Experiments from the current study demonstrated that CBX6 expression was frequently downregulated in breast cancer. Notably, CBX6 was silenced epigenetically by EZH2 in a PRC2-dependent manner. In functional analyses, overexpression of CBX6 resulted in cell proliferation inhibition, induced cell cycle arrest and dramatically suppressed the migration and invasion capacities of MCF-7 cells. Furthermore, CBX6 induced significant downregulation of BST2 via binding to its promoter region to exert potential antitumor activity.
Results
CBX6 is frequently downregulated in human breast cancer. To determine the specific role of CBX6 in breast cancer, we comprehensively analyzed The Cancer Genome Atlas (TCGA) dataset for aberrant expression of this gene (GSE62944). Significant downregulation of CBX6 was observed in breast cancer tissues compared with controls, as shown in Fig. 1A . Gene expression profiling experiments have facilitated the identification of several subtypes of breast cancer, including luminal A, luminal B, HER2-enriched, and basal-like. Examination of the TCGA dataset revealed that CBX6 is not differentially expressed in different subtypes of breast cancer ( Supplementary Fig. S1A ). CBX6 expression was further analyzed in breast cancer samples with different histological grades. Our data showed similar expression profiles of CBX6 at different stages ( Supplementary Fig. S1B ).
To extend these observations, we tried to examine the expression of CBX6 by immunohistochemistry (IHC) in normal breast and breast cancer tissues. The signals detected using the CBX6 antibody (Millipore 09-030) are mainly located in the cytoplasm and connective tissues ( Supplementary Fig. S2A ). We interpreted that the IHC signal generated from this antibody was nonspecific, because CBX6 is primarily a nuclear protein as revealed by the immunofluorescence analysis of GFP-CBX6 fusion in MCF-7 cells (Supplementary Fig. S2B ). The antibody recognized CBX6 immunoprecipitated from cell lysates ( Supplementary Fig. S2C ), and a band at the correct molecular weight of CBX6 in total cell lysates, but showed cross-reactivity with nonspecific bands of higher molecular weight. Next, the expression of CBX6 was assessed by qRT-PCR and by Western blotting using the antibody (Millipore 09-030) in a human non-tumorigenic epithelial cell line, MCF-10A, and two human breast adenocarcinoma cell lines, MCF-7 and MDA-MB-231. Consistently, CBX6 was significantly downregulated in breast cancer cells, compared with non-tumorigenic epithelial cells (Fig. 1B) . In view of these findings, the association between CBX6 levels and clinical progression of breast cancer was further explored. Kaplan-Meier survival analysis of the TCGA breast cancer dataset showed the overall survival time did not significantly differ between patients with high CBX6 expression and low CBX6 expression when bifurcating gene expression at the median (HR = 0.94, P = 0.61) (Fig. 1C) . However, survival analysis by the Kaplan-Meier plotter 29 , which curated the survival and gene expression data (Affymetrix microarray platform) of 5,143 breast cancer patients deposited in GEO 29 , showed patients with high CBX6 expression displayed significantly longer overall survival (OS) (HR = 0.78, P = 0.021) and recurrence-free survival (RFS) (HR = 0.73, P = 2.7e-08) than those with lower CBX6 expression 30 ( Supplementary Fig. S3 ). The discrepancy between the two datasets suggests the correlation between CBX6 expression and breast cancer patient survival needs further study.
EZH2 negatively regulates CBX6 in breast cancer. The mechanisms underlying CBX6 downregulation in breast cancer are not known at present. To identify the specific regulatory factors of CBX6 expression, we data-mined the ChIP-sequencing (ChIP-Seq) datasets deposited in the Gene Expression Omnibus (GEO). Interestingly, EZH2 and H3K27me3 peaks were detected at the CBX6 promoter in human mammary epithelial cells (HMEC) (Supplementary Fig. S4A ), and a negative correlation between EZH2 and CBX6 expression was observed in MCF-10A, MCF-7, and MDA-MB-231 cells ( Supplementary Fig. S4B ). EZH2, which is highly expressed in breast cancer, promotes tumor progression and is associated with poorer patient outcome 31 . To further ascertain whether EZH2 is involved in regulation of CBX6, we performed overexpression and knockdown experiments in MCF-7 cells. CBX6 levels were markedly decreased upon EZH2 overexpression ( Fig. 2A) . Conversely, knockdown of EZH2 led to significant upregulation of CBX6 (Fig. 2B) . Examination of the TCGA dataset further confirmed the negative correlation between EZH2 and CBX6 expression patterns in breast cancer (Spearman r = −0.209, P < 0.0001) (Fig. 2C) .
Regulation of CBX6 expression by EZH2 is PRC2-dependent. The gene regulatory activity of EZH2
can either be PCR2-dependent or -independent. Accordingly, we investigated whether or not EZH2-mediated downregulation of CBX6 is influenced by PRC2. To this end, MCF-7 cells were treated with the EZH2 inhibitor, EPZ-6438. As shown in Fig. 3A , following EPZ-6438 treatment, the H3K27me3 level was dramatically decreased and that of CBX6 was significantly increased in MCF-7 cells. EED, a core component of PRC2, is indispensable for PRC2 activity. We employed three different siRNAs for EED knockdown in MCF-7 cells, which all led to a marked increase in CBX6 expression (Fig. 3B ). In addition, EZH2 overexpression no longer affected CBX6 expression after EED knockdown in MCF-7 cells (Fig. 3C) . Furthermore, H3K27me3 enrichment at the CBX6 promoter was detected using ChIP-qPCR (Fig. 3D ), indicating regulation of CBX6 expression by EZH2 is PRC2-dependent.
CBX6 inhibits proliferation and induces cell cycle arrest in MCF-7 cells.
To determine the biological significance of CBX6 dysregulation, we generated stable MCF-7 cell lines expressing vector alone or FLAG-tagged CBX6 (Fig. 4A ) and examined the effects of CBX6 overexpression on cell growth. As shown in Fig. 4B , CBX6-overexpressing MCF-7 cells grew moderately slower, compared with control cells transfected with the empty vector. Moreover, CBX6-overexpressing cells formed fewer and smaller colonies relative to the control group (empty vector) ( Fig. 4C upper panel) . This effect was further confirmed by measuring absorbance after solubilization of cell-bound crystal violet (Fig. 4C , lower panel). To assess whether the lower growth rate of CBX6-overexpressing cells is attributable to alterations in the cell cycle, we examined cell cycle distribution via flow cytometry. Our data showed a higher percentage of CBX6-overexpressing cells in the G1 phase and a lower percentage in the S phase, compared with control cells expressing empty vector (Fig. 4D ).
CBX6 inhibits migration and invasion of MCF-7 cells. Metastasis is an essential hallmark of cancer.
To investigate the effects of CBX6 on metastasis and invasion, we performed cell migration and invasion assays in vitro. In the wound healing assay, CBX6-overexpressing MCF-7 cells showed delayed wound healing closure, compared to control cells (Fig. 5A) . Similarly, CBX6 overexpression induced a dramatic reduction in migration and invasion of MCF-7 cells in a Transwell assay (Fig. 5B,C) .
Gene expression changes induced by CBX6 overexpression.
To clarify the mechanisms underlying CBX6 activity in breast cancer progression, MCF-7 cells stably overexpressing the gene were subjected to microarray analysis. In total, 525 genes were differentially expressed between CBX6-overexpressing and vector control cells, among which 234 were downregulated (log 2 fold change <−0.6, P < 0.05) and 291 were upregulated (log 2 fold change >0.6, P < 0.05) in CBX6-overexpressing cells ( Fig. 6A ; Supplementary Table S2) . Gene ontology analysis revealed that upregulated genes in CBX6-overexpressing cells are involved in epithelial cell differentiation and epithelium development whereas downregulated genes participate in the cell cycle, cell division, cell migration, cell development, regulation of intracellular signal transduction and cellular response to stress (Fig. 6B) .
To gain more insights into the functional consequences of restoring CBX6 expression in MCF7 cells, we performed gene set enrichment analysis (GSEA), and found that multiple cell cycle genes, included qRT-PCR analysis of EZH2 and CBX6 mRNA in control (empty vector) and EZH2-overexpressing cells using GAPDH for normalization. Data are presented as means ± S.D. from three independent experiments performed in triplicate. *P < 0.05. Right panel: Western blot analysis of EZH2 and CBX6 protein levels in control (empty vector) and EZH2-overexpressing cells using GAPDH as a loading control. MCF-7 cells were transiently transfected with an empty or EZH2 vector for 48 hours, then cells were harvested, and total RNA and proteins were extracted for analysis. (B) Knockdown of EZH2 using siRNA leads to upregulation of CBX6. Left and middle panels: qRT-PCR analysis of EZH2 and CBX6 mRNA levels in siRNA control and EZH2 knockdown cells using GAPDH for normalization. Data are presented as means ± S.D. from three independent experiments performed in triplicate. *P < 0.05. Right: Western blot analysis of protein levels in siRNA control and EZH2 knockdown cells using GAPDH as a loading control. MCF-7 cells were transfected with control siRNA or siEZH2, total RNA and protein were extracted 48 h post-transfection for analysis. (C) Spearman's rank correlation coefficient indicating a negative correlation between CBX6 and EZH2 mRNA levels in breast cancer tissues based on The Cancer Genome Atlas (TCGA) RNA-Seq data. in the gene matrices of the Kyoto Encyclopedia of Genes and Genomes (KEGG) Cell cycle, REACTOME cell cycle, REACTOME cell cycle checkpoints and REACTOME G2_M checkpoints, are downregulated in CBX6-overexpressing (CBX6-OE) MCF-7 cells (Fig. 6C) . Specifically, several cyclins including G1/S Cyclin CCND1 and CCNE1 are downregulated in CBX6-OE MCF-7 cells, consistent with the slight G1-arrest in CBX6-OE cells. Meanwhile, the cyclin-dependent kinase inhibitor gene, including CDKN1B (p27), CDKN1A (p21) are upregulated in CBX6-OE MCF-7 cells. CDKN2A (p16 INK4A /p14 ARF ) is a known Polycomb target gene 32 ; its expression is downregulated in CBX6-OE MCF-7 cells. Paradoxically, CDK2B, the neighboring gene of CDKN2A, is upregulated in CBX6-OE MCF-7 cells. MYC, the oncogene which amplifies the output of the existing gene expression program 33 , and promotes tumorigenesis by regulating cell growth, proliferation and metabolism 34 , is downregulated by CBX6 overexpression (Fig. 6D ). All these results indicate that CBX6 governs a complex gene expression program.
BST2 is directly downregulated by CBX6.
PcG proteins have context-dependent actions on gene expression 35 . We reasoned high-confidence direct targets of CBX6 should have a greater tendency to be modulated by CBX6 in different cell line models. To ascertain potentially significant genes in the CBX6-associated tumorigenesis, we performed microarray analysis on a U251MG glioma cell line overexpressing CBX6 that we previously BST2, which encodes a type II integral membrane protein that inhibits the release of enveloped viruses through its homodimerization 36, 37 , is overexpressed in multiple cancers including breast cancer 37 . BST2 was demonstrated to promote tumor survival, invasion and metastasis through a plethora of mechanisms 37, 38 . We applied qRT-PCR and western blot analyses to confirm the regulation of BST2 by CBX6. As expected, overexpression of CBX6 in MCF-7 cells was associated with decreased levels of BST2 mRNA and protein (Fig. 7A) . Examination of the CBX6-OE U251MG cells and its control revealed that overexpression of CBX6 also caused a significant decrease in BST2 in U251MG cells (Fig. 7B) . We further determined whether CBX6 directly targets BST2. As shown in Fig. 7C , both CBX6 and H3K27me3 were significantly enriched at the BST2 promoter in CBX6-OE MCF-7 cells. Moreover, examination of TCGA dataset disclosed a marked increase in BST2 expression in breast cancer (Supplementary Fig. S5 ) and CBX6 and BST2 were negatively correlated in breast cancer (Spearman r = −0.1804, P < 0.0001) (Fig. 7D) . Based on these findings, we propose that CBX6 potentially plays a tumor suppressor role through repression of BST2 in breast cancer. 
Discussion
PcG-mediated gene silencing plays a critical role in cancer development. CBX6, a subunit of PRC1, reads the crucial epigenetic marker, H3K27me3, written by PRC2. Recent studies have reported that CBX6 assembles into PRC1 and its knockdown via shRNA induces spontaneous differentiation of embryonic stem cells (ESC), supporting a role as an essential regulator of ESC identity 39 . Ectopic expression of CBX6 is reported to block reprogramming 40 and its dysregulation implicated in different types of malignancies 23, 24 . Experiments in the current study revealed significant downregulation of CBX6 in breast cancer. CBX6 inhibited cell proliferation and induced cell cycle arrest in MCF-7 in vitro. Moreover, cell migration and invasion rates were significantly reduced upon CXB6 overexpression.
We examined changes in gene expression profiles caused by CBX6 overexpression via microarray analysis. Consistent with functional experimental results, genes downregulated in association with CBX6 overexpression are involved in the cell cycle, division and migration. For example, CBX6 represses expressions of G1/S Cyclin CCND1 and CCNE1 in MCF-7 cells. Both CCND1 and CCNE1 were reported to be repressed by PcG proteins: CBX7, a paralog of CBX6, binds the CCNE1 prompter and represses the expression of CCNE1 partly through HDAC2 in mice and human lung carcinomas and gliomas 41, 42 ; JARID2, a co-factor facilitating genomic targeting of PRC2, represses CCND1's expression in cardiomyocytes and leukemia [43] [44] [45] . In this study, we also found CBX6 repressed MYC expression in MCF-7 cells. Kaur et al. reported that MYC limits its own expression by a feedback loop mediated by EZH2 46, 47 , the finding here suggests CBX6 might participate in the process. In addition to amplifying transcription, paradoxically, MYC represses discrete sets of genes through direct and indirect mechanisms 48 . Best characterized MYC-repressed genes include CDKN1A, CDKN1B and CDKN2B 48 , all of which are upregulated in the MCF-7 cell upon CBX6 over-expression, suggesting a potential CBX6-MYC-CDK inhibitors pathway regulating cell cycle progression. Nevertheless, the results here indicate that CBX6 regulates complex regulatory circuits, further research is needed to ascertain the effects of CB6 on gene expression, elucidate the detailed mechanisms by which CBX6 controls gene expression, directly or indirectly. Ctrl   FZR1  ATM  ANAPC2  MDM2  ANAPC7  ATR  CDKN1A  DBF4  CDC23  EP300  CDKN1B  CCNB1  MAD2L2  RBX1  CCNA1  CDK7  ZBTB17  SMAD3  SKP1  MAD1L1  RBL2  CDC14A  CDKN2B  CDC25B  CDK4  STAG2  YWHAB  E2F5  CDK6  HDAC2  YWHAZ  RAD21  E2F1  PCNA  YWHAG  WEE1  PTTG2  CCNH  SMAD2  GADD45G  CREBBP  CDC25C  ANAPC11  CCNB2  PRKDC  GSK3B  E2F4  CDC16  CDKN2D  CCNE2  ANAPC1  LOC650621  CDKN1C  SMAD4  TFDP2  GADD45A  BUB1  YWHAQ  CDC25A  STAG1  ESPL1  MCM5  TGFB3  HDAC1  MCM6  CCNE1  MCM3  ABL1  ANAPC4  SKP2  CDKN2A  PLK1  PTTG1  GADD45B  LOC731751  CDC7  ANAPC5  RBL1  CHEK2  E2F3  E2F2  BUB3  MAD2L1  YWHAH  SFN  CDC14B  CHEK1  CDC20  CDK2  CCNA2  TTK  YWHAE  MCM2  TP53  TGFB2  CCND1  MCM4  TFDP1  MCM7  CDC26  CUL1  ANAPC13  RB1  CDC6  CCND3  ANAPC10  SMC3  PKMYT1  MYC  BUB1B CBX6-OE Ctrl Z-score In addition to breast cancer, CBX6 is reported to be downregulated in glioblastomas although the underlying mechanisms are still unknown. EZH2 is highly expressed in multiple cancers, including glioblastoma and breast cancer. Moreover, high expression of EZH2 is associated with aggressive disease and poor outcome [49] [50] [51] . To date, several small molecule inhibitors targeting EZH2 have been investigated in preclinical and clinical trials 52 . PcG proteins are suggested to auto-regulate their own expression in human embryonic fibroblasts 53 . Overexpression and knockdown experiments in the current study showed that EZH2, the catalytic subunit of PRC2, repressed the expression of CBX6. Earlier studies suggest that gene expression regulated by EZH2 is either PRC2-dependent or independent 54, 55 . Here, we observed upregulation of CBX6 expression by the EZH2 inhibitor EPZ-6438. Knockdown of EED led to upregulation of CBX6 in MCF-7 cells. Additionally, EZH2 overexpression did not affect CBX6 expression after knockdown of EED in MCF-7 cells. Our data collectively indicate that downregulation of CBX6 by EZH2 requires intact PRC2 activity.
Bone marrow stromal cell antigen 2 (BST2), also known as CD317 or tetherin, is a lipid raft-associated type 2 transmembrane glycoprotein. BST2 promotes activation of NF-kB, leading to the production of proinflammatory factors involved in inhibition of viral replication 56, 57 and additionally implicated in blocking virion release via physically tethering to the cell surface 58 . BST2 may be involved in cell-to-cell interactions in view of the finding that purified extracellular domains of the protein inhibit the adhesion of human monocytes to HUVECs 59 . Inflammatory responses and cell adhesion contribute to tumorigenesis, indicating a role in cancer progression. Accumulating studies have provided evidence that BST2 is involved in tumor progression in many cancer types, including breast cancer [60] [61] [62] [63] [64] [65] [66] [67] . Yi et al. demonstrated that BST2 is upregulated in tamoxifen-resistant breast cancer cells and enhances the invasion and migration capacities of tumor cells. Mahauad-Fernandez's research group reported that knockdown of BST2 inhibits mammary tumor growth and metastasis, both in vitro and in vivo, and high BST2 expression in breast tumors is positively associated with tumor size and aggressiveness as well as poor patient survival 63 . In addition, monoclonal antibodies against BST2 possess significant antitumor activity in lymphoma and endometrial cancers 68, 69 . In view of the combined results, BST2 is proposed as an ideal therapeutic target for breast cancer. In the current study, CBX6 significantly suppressed BST2 expression in both MCF-7 and U251MG cells, implying that this process is independent of cell type. Additionally, CBX6 bound directly to the BST2 promoter and increased enrichment of H3K27me3.
In conclusion, our experiments provide evidence of significant downregulation of CBX6 expression in breast cancer. CBX6 was negatively regulated by EZH2 in a PRC2-dependent manner. Overexpression of CBX6 inhibited the proliferation and metastasis capacity in breast cancer cells in vitro, altered the expression of genes involved in cell cycle regulation and other pathways. Moreover, CBX6 exerted a marked suppressive effect on expression of BST2 through binding to its promoter and altering histone modification. To our knowledge, this is the first study to demonstrate a tumor suppressor role of CBX6 in breast cancer.
Methods
Bioinformatic analysis. mRNA expression profiles and clinical information on the 1119 breast carcinomas and 113 normal samples were obtained from The Cancer Genome Atlas (TCGA) data portal. Gene set enrichment analysis 70 was performed as described 71 . Kaplan-Meier survival analyses were performed using GraphPad Prism 6 or the Kaplan-Meier plotter (www.kmplot.com) 29 .
Cell culture and drug treatment. MCF-7 and MDA-MB-231 were kindly provided by Professor Edwin Chong Wing Cheung (Faculty of Health Sciences, University of Macau) and MCF-10A by Professor Lijun Di (Faculty of Health Sciences, University of Macau). C2C12 was purchased from the Cell Resources Center of Shanghai Institute for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). MCF-7, MDA-MB-231 and C2C12 cells were cultured in DMEM (Gibco) containing 10% FBS. MCF10A cells were cultured in DMEM supplemented with 10% FBS, 0.5 µg/mL hydrocortisone (Sigma), 10 µg/mL insulin (Thermo Fisher), and 20 ng/mL hEGF (Thermo Fisher). All cells were tested negative for mycoplasma contamination and were maintained at 37 °Cand 5% CO 2 . For drug treatment, MCF-7 cells were seeded in 6-well plates and incubated overnight, followed by treatment with 50 µm EPZ6438 (Selleck Chemicals). Control cells were treated with 0.1% DMSO. All cells were treated for 5 consecutive days followed by extraction of protein and RNA for analysis.
Plasmids and transfection.
Human CBX6-Myc-DDK cloned into pCMV6_Entry was purchased from OriGene (RC204166). Human EZH2 was amplified using cDNA derived from MCF-7 cells as a template and cloned into pcDNA3.2/GW/D-TOPO expression vector (Invitrogen). Expression vectors were transfected into MCF-7 cells with Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Cells transfected with the corresponding empty expression vector served as the controls. At 48 h post-transfection, protein and RNA were isolated for analysis. For generating a CBX6-expressing stable cell line, 1 mg/mL G418 (Gibco) was added to the culture medium to screen for stable clones. Expression of CBX6 mRNA and protein was verified via qRT-PCR and western blot analysis, respectively. For knockdown experiments, a pool of siRNAs targeting EZH2 (Santa Cruz Biotechnology; sc35312) and three EED siRNAs (Integrated DNA Technologies (IDT)) were employed. MCF-7 cells were transfected with test or control siRNA at a final concentration of 50 nM using Lipofectamine RNAiMAX transfection reagent (Invitrogen) according to the manufacturer's instructions. At 48 h post-transfection, protein and RNA were harvested for analysis.
Cell proliferation assay. MCF-7 cells (2 × 10
3 ) were plated in 96-well plates in 100 µL medium. Cell proliferation was analyzed using the CellTiter-Glo ® Luminescent Cell Viability Assay (Promega) for five consecutive days.
Colony formation assay. MCF-7 cells were seeded into 6-well plates at a density of 500 cells per well. At 15 days after seeding, each well was stained with 0.1% crystal violet and methanol added to solubilize the dye. Absorbance at 540 nm was read using a Spark Multimode microplate reader (Tecan).
Flow cytometry analysis of the cell cycle. MCF-7 cells were seeded into 6-well plates and synchronized via starvation (without serum) for 24 h, followed by culturing under normal conditions for 24 h. Cells were harvested and stained using cell cycle and apoptosis analysis kits (Beyotime) and analyzed with a FACS scan flow cytometer (BD Biosciences). The relative ratios of G1, S, and G2 phases were analyzed using the FlowJo 2.8 software.
Wound healing assay. MCF-7 cells were seeded into 6 well-plates. After cells reached 90% confluence, cross lines were generated using a sterile pipette tip. Images of cells were obtained after 0, 12 and 36 h post-wounding using the EVOS FL cell imaging system (Thermo Fisher).
Transwell assay. The Transwell assay was performed in 24-well chambers (Corning). For the migration assay, 2.5 × 10 5 cells were resuspended in serum-free medium and added to the upper chamber. The bottom chamber was filled with 500 μL culture medium containing 10% FBS. After culturing for 24 hours, cells on the lower surface of the membrane were stained with 0.1% crystal violet and photographed using the Carl Zeiss Axio Observer microscope. For the invasion assay, the upper chamber surface of the basement membrane of the Transwell was coated with Matrigel (Corning). Aliquots of cells (1 × 10 6 ) were resuspended in serum-free medium and added to the upper chamber. The bottom chamber was filled with 500 μL culture medium containing 10% FBS. After culturing for 36 hours, cells on the lower surface of the membrane were stained with 0.1% crystal violet and photographed using the Carl Zeiss Axio Observer microscope.
Total RNA extraction. Total RNA was extracted using the TRIzol reagent (Invitrogen). Genomic DNA was digested with an RNase-free DNase kit (Qiagen) and subsequently purified using the RNeasy Mini Kit (Qiagen) following the manufacturer's instructions. The concentration and quality of RNA were determined using an Agilent 2100 Bioanalyzer (Agilent Technologies).
Gene expression profiling and analysis. Total RNA was amplified and labeled using the TargetAmp ™ -Nano Labeling Kit for Illumina Expression BeadChip (Epicentre Biotechnologies). Labeled cRNA was purified with the RNeasy mini kit (Qiagen) and hybridized on HumanHT-12 v4 Expression BeadChip microarrays (Illumina) according to the manufacturer's protocol. Hybridized arrays were scanned using the Illumina iScan, and the image data was extracted using the Illumina Genome Studio software. Gene ontology analysis was conducted using the PANTHER Overrepresentation Test (http://www.geneontology.org/).
Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR).
Total RNA (1 μg) was used to synthesize cDNA using a PrimeScript ™ RT Reagent Kit with gDNA Eraser (Takara). Quantitative PCR (qPCR) was conducted using the iTaq ™ Universal SYBR ® Green Supermix (Bio-Rad) in the CFX 96 thermocycler (Bio-Rad). Assays were performed in triplicate and repeated three times. The relative expression level of the gene of interest was normalized to that of GAPDH and calculated according to the 2−ddCt method. The primers used in this study are presented in Supplementary Table S1 .
Western blot. Whole cell lysates were harvested using RIPA Lysis and Extraction Buffer (Invitrogen) sup- Supplementary Table S1 .
